Trade CCCC anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
C4 Therapeutics, Inc. (CCCC) is trading at US$3.76, up 0.53% today as of Sep 4, 16:00 EDT. The company has a market capitalisation of US$492.1M. Over the past 52 weeks, CCCC has traded between US$1.69 and US$5.17. On Syfe you can trade CCCC with $0 commission and add it to your watchlist.
| Previous close | US$3.74 |
|---|---|
| Market cap | US$492.1M |
| 52-week range | US$1.69 – US$5.17 |
| Volume | 2.36M |
| Exchange | US |
Add to Watchlist
Set Price Alert
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in 2015 and is headquartered in Watertown, MA.
Year: 2020
C4 Therapeutics Expands Roche Partnership to Develop Degrader-Antibody Conjugates Against Cancer
Apr 9, 12:10 PM · MT Newswires
C4 Therapeutics Doses First Patient in Phase 1b Trial of Multiple Myeloma Combination Treatment
Mar 25, 11:49 AM · MT Newswires
C4 Therapeutics, Inc. (CCCC) stock is trading at US$3.76, +0.53% from the previous close of US$3.74.
The market cap for C4 Therapeutics, Inc. (CCCC) stock is approximately US$492.1M.
The 52-week high for C4 Therapeutics, Inc. (CCCC) stock is US$5.17.
The 52-week low for C4 Therapeutics, Inc. (CCCC) stock is US$1.69.
C4 Therapeutics, Inc. (CCCC) does not currently pay a dividend.
Stay on top of CCCC
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
